NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada (TASE:KMDA), a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has entered into an exclusive agreement with a large US specialty pharmaceutical distributor company for the distribution of its flagship product, intravenous alpha-1 antitrypsin (AAT-IV) in the United States.
